Navigation Links
deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
Date:2/2/2009

REYKJAVIK, Iceland, February 2 /PRNewswire-FirstCall/ --

Scientists from deCODE genetics (Nasdaq: DCGN) today report the discovery of the first variation in the sequence of the human genome ever shown to confer increased risk of essential tremor. The single-letter variant (or SNP) was discovered by analyzing the genomes of a total of more than 16,000 patients and healthy subjects from Iceland, Austria, Germany and the United States. It is located on the long arm of chromosome 15 in the LINGO1 gene, which encodes a protein that has been shown to affect how neurons are formed and signal each other. This makes the finding even more significant, for although essential tremor is a relatively common neurological condition, to date little has been known about the biology behind it. Variations in LINGO1 may contribute to neuronal degeneration and to inhibit normal processes of neuronal repair that may be involved in essential tremor, and the protein itself may provide a potentially effective target for the development of drugs to treat the condition. The paper, "Variant in the sequence of the LINGO1 gene confers risk of essential tremor," is published today in the online edition of Nature Genetics, at http://www.nature.com/ng.

"This discovery is an encouraging direct hit. It offers a clear example of how genetics can both increase our understanding of what a disease is and directly point the way to the development of new therapies. This SNP is in a gene involved in many of the processes that one would expect to be perturbed in patients with essential tremor. Because LINGO1 has be shown to have a negative impact on neuronal development and survival, inhibiting it with a small molecule drug may provide an effective approach for developing a treatment for the severe forms of essential tremor. We are very excited to have taken the first step in this process," said Kari Stefansson, CEO of deCODE.

Essential tremor is characterized by involuntary trembling of the arms and hands, and in many cases of the head and voice as well. It is frequently mild enough that many patients do not seek any medical attention, though in severe cases it can impair eating, drinking, writing and other daily activities, and some patients with the most debilitating symptoms will seek surgery to control it. It appears in some individuals when they are in their twenties and thirties, but becomes more common in later life and is believed to affect as many as 1 in 7 people over the age of 65. Approximately 20% of the general population carry one copy of the at-risk version of the SNP and 5% carry two copies, corresponding to a roughly 55% and 140% higher likelihood of developing the condition than individuals who carry no copies of the risk variant.

deCODE and its collaborators at Vienna, Tubingen and Emory universities would like to thank the individuals who took part in this study.

About decode

deCODE is a bio-pharmaceutical company developing drugs and DNA-based tests to improve the treatment, diagnosis and prevention of common diseases. Its lead therapeutic programs, which leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 modulators with therapeutic applications in Alzheimer's disease and other conditions. deCODE is a global leader in human genetics, and has identified key variations in the genome (SNPs) conferring increased risk of major public health challenges from cardiovascular disease to cancer. Based upon these discoveries deCODE has brought to market a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases. Through its CLIA-registered laboratory, deCODE is offers deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and deCODE BreastCancer(TM), for the common forms of breast cancer. deCODE is delivering on the promise of the new genetics (SM). Visit us on the web at http://www.decode.com; on our diagnostics site at http://www.decodediagnostics.com; for our pioneering personal genome analysis service and new Cardio and Cancer scans, integrating the genetic variants included in these tests and those linked to another twenty common diseases, at http://www.decodeme.com; and on our blog at http://www.decodeyou.com.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, the effect of a potential delisting of our common stock from The Nasdaq Global Market, uncertainty regarding potential future deterioration in the market for auction rate securities which could negatively affect our cash position and result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10-K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

    Contacts:
    Edward Farmer
    +354-570-2819
    edward.farmer@decode.is

    Gisli Arnason
    +354-570-1825
    gisli.arnason@decode.is

    Joy Bessenger
    +1-212-481-3891
    joy.bessenger@decode.is


'/>"/>
SOURCE DeCODE Genetics Inc
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. deCODE Sells Auction Rate Securities
2. Introducing deCODEme Cardio(TM) and deCODEme Cancer(TM)
3. deCODE Discovers Common Genetic Variations Contributing to Low Bone Mineral Density and Risk of Osteoporosis
4. deCODE to Integrate New Genetic Risk Factor for Type 2 Diabetes Into Its deCODEme(TM) Personal Genome Scan Service
5. Major Independent Study Underscores Utility of deCODE MI(TM) for Better Predicting Risk of Heart Attack, Informing Statin Therapy
6. deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke
7. deCODE genetics Announces Third Quarter 2008 Financial Results
8. deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter
9. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2008 Financial Results
10. deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer
11. deCODE Receives Nasdaq Deficiency Notice Relating to Market Value
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... 2017 , ... AxioMed president, Jake Lubinski, describes the AxioMed ... deformed, which is identical to how the human discs work to distribute force. ... to its natural state along a hysteresis curve, exactly like a healthy human ...
(Date:3/23/2017)... 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), ... for solid tumor cancers, today announced that yesterday ... announced last Friday, March 17, 2017. ... securities totaling 28,843,692 shares, comprised of 18,843,692 common ... of Class C Warrants pre-funded at the closing ...
(Date:3/23/2017)... -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical ... reported financial results for the quarter and year ... update on the company,s clinical development efforts and ... pleased to report that last year was a ... Krammer. "We achieved key clinical milestones and attracted ...
(Date:3/23/2017)... , March 23, 2017 NetworkNewsWire ... ... death, putting significant strain on health care systems, in terms ... diagnoses rises, so too does the development of innovative and ... side effects. Among the many types of cancer treatments, a ...
Breaking Biology Technology:
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, 2017 /PRNewswire/ ... 23andMe , the leading personal genetics company, are ... can now provide customers with personalized nutrition plans that ... biometrics, but also genetic markers impacting how their body ... personalized food decision support platform uses biometrics such as ...
(Date:3/6/2017)... March 6, 2017 Mintigo , ... today announced Predictive Sales Coach TM , its ... sales intelligence into Salesforce. This unique AI application ... sales organizations with deep knowledge of their customers ... intelligent engagement. Predictive Sales Coach extends Mintigo,s existing ...
(Date:3/2/2017)... 2017 Who risk to be deprived of ... full report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND ... Fingerprint sensors using capacitive technology represent a fast ... Idex forecasts an increase of 360% of the number ... the fingerprint sensor market between 2014 and 2017 (source ...
Breaking Biology News(10 mins):